New Price Conversion Method of Anti-cancer Drugs under the Buy-and-gift Strategy Based on Survival Data
- VernacularTitle:实施买赠策略的抗癌药品基于生存数据的价格折算新方法
- Author:
Gaojie LI
1
;
Lei CHEN
1
;
Xiaoyu XI
1
Author Information
1. Research Center of National Drug Policy & Ecosystem，China Pharmaceutical University，Nanjing 211198，China
- Publication Type:Journal Article
- Keywords:
Buy-and-gift strategy;
Anti-cancer drugs;
Survival data;
Aid model;
Drug price conversion;
Algorithm
- From:
China Pharmacy
2021;32(17):2049-2053
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE：To provid e a more accurate calculation method for the determination of drug negotiation base price ， pharmacoeconomic calculation and budget impact analysis and calculation in the process of medical insurance access with buy-and-gift strategy. METHODS ：By the model method and literature research ，understanding the existing price conversion methods of the anti-cancer drugs that currently implement the buy-and-gift strategy ，a new method of drug price conversion was explored on the basis of the survival data of patients in different disease states ，and the core idea and calculation process of the algorithm were analyzed by an example. RESULTS ：The new algorithm was combined with the survival data of patients under different disease states. Its calculation process mainly included obtaining the actual duration of medication use per unit cycle and the theoretical amount of medication ，determining the aid model for anti-cancer drugs under buy-and-gift strategy ，converting the actual price. The simulation calculation was carried out under the one-step drug donation mode ，periodic drug donation mode and preferential installment drug donation mode. CONCLUSIONS ：The conversion method of anti-cancer drug price under buy-and-gift strategy based on survival data makes up for the shortcoming that the existing calculation methods are difficult to reflect the actual price of anti-cancer drugs ，and provides a new calculation method for calculating the actual reference price of anti-cancer drugs for medical insurance access.
